Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer

Journal of Immunology

Volumn 166, Issue 1, 2001, Pages 678-689

  Almand, B ^a   Clark, J I ^a   Nikitina, E ^a   Van Beynen, J ^a   English, N R ^a   Knight, S C ^a   Carbone, D P ^a   Gabrilovich, D I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RETINOIC ACID;

ADULT; AGED; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER IMMUNOLOGY; CANCER PATIENT; CELL DIFFERENTIATION; CLINICAL ARTICLE; COLONY FORMATION; DENDRITIC CELL; ELECTRON MICROSCOPY; FLOW CYTOMETRY; HEAD AND NECK CARCINOMA; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE DEFICIENCY; LUNG NON SMALL CELL CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0035164478     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.1.678     Document Type: Article

References (37)

1. Dendritic cells and the control of immunity
2. Cancer
3. Human renal-cell carcinoma tissue contains dendritic cells
4. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells
5. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation
6. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats
7. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: In vitro restoration of this immunosuppression by thymic hormones
8. Decreased antigen presentation by dendritic cells in patients with breast cancer
9. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-beating hosts
10. Defective function of Langerhans cells in tumor-beating animals is the result of defective maturation from hematopoietic progenitors
11. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors
12. Circulating dendritic cells in early and advanced cancer patients: Diminished percent in the metastatic disease
13. Clinical significance of defective dendritic cell differentiation in cancer
14. + T cells
15. Developmental regulation of MHC class II transport in mouse dendritic cells
16. Proliferating dendritic cell progenitors in human blood
17. Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability
18. Nitric oxide and macrophage function
19. Nitric oxide mediation of active immunosuppression associated with graftversus-host reaction
20. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
21. All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia
22. Acute promyelocytic leukemia
23. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
24. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage-colony-stimulating factor
25. Serum dependent downregulation of CD1 a expression and specific CTL priming activity in human dendritic cells
26. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages
27. Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10
28. + cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells
29. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid
30. Detection of leukemic clone maturation in vivo by premature chromosome condensation
31. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results
32. Differentiation therapy of acute promyelocytic leukemia with tretinoin (alltrans-retinoic acid)
33. + BM cells
34. Retinoic acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells
35. Modulation of growth factor receptors on acute myeloblastic leukemia cells by retinoic acid
36. Retinoic acid combined with GM-CSF induces morphological changes with segmented nuclei in human myeloblastic leukemia ML-1 cells
37. The effects of retinoids on dendritic cell function